Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.5%

9 terminated/withdrawn out of 78 trials

Success Rate

83.6%

-2.9% vs industry average

Late-Stage Pipeline

10%

8 trials in Phase 3/4

Results Transparency

2%

1 of 46 completed trials have results

Key Signals

11 recruiting1 with results4 withdrawn

Enrollment Performance

Analytics

N/A
40(61.5%)
Phase 2
10(15.4%)
Phase 1
6(9.2%)
Phase 4
5(7.7%)
Phase 3
3(4.6%)
Early Phase 1
1(1.5%)
65Total
N/A(40)
Phase 2(10)
Phase 1(6)
Phase 4(5)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (78)

Showing 20 of 78 trials
NCT07645443Not ApplicableRecruiting

FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis

Role: collaborator

NCT07544498Not ApplicableNot Yet Recruiting

XR2ESILIENCE - XR-Based Resilience Training for Stress and Mental Health in Healthcare Workers

Role: collaborator

NCT06626789Phase 1Recruiting

Brain Signal Training to Enhance Affect Down-regulation

Role: lead

NCT06456983Not ApplicableRecruiting

Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial

Role: lead

NCT02926859Phase 2Active Not Recruiting

Enhancing Recovery in Early Schizophrenia

Role: lead

NCT06845124Phase 2Recruiting

A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence

Role: lead

NCT06959342Not ApplicableRecruiting

Modification of Inhibitory Control and Craving Through Transcranial Direct Current Stimulation (tDCS) as an Add-On Treatment for Substance Use Disorder

Role: lead

NCT03816527Withdrawn

Selective Attention in Alcohol Use Disorder

Role: lead

NCT06346353Completed

Substance Consumption, Personality, and Cognitive Functioning of Chess Players

Role: lead

NCT05698615Not ApplicableCompleted

Chess Training as add-on Intervention for Adolescents With Psychiatric and Psychosomatic Disorders

Role: lead

NCT06105853Not ApplicableRecruiting

Neurobehavioral Profiles of Adaptive Stress Responses in Individuals With Alcohol Use Disorder

Role: lead

NCT03765476Not ApplicableActive Not Recruiting

Validation of a Training Program for Patients With Alcohol Use Disorder

Role: lead

NCT03911726Not ApplicableActive Not Recruiting

Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With Schizophrenia

Role: lead

NCT02438202Not ApplicableNot Yet Recruiting

Electroconvulsive Therapy for Treatment of Alzheimer´s Disease

Role: lead

NCT06881810Phase 2Recruiting

Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment

Role: lead

NCT00916201Phase 1Withdrawn

Evaluation Study of New Compounds With Potential Use in Schizophrenia

Role: lead

NCT02492074Phase 1Withdrawn

Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study

Role: lead

NCT05726045Not ApplicableRecruiting

Increasing Smoking Cessation Success Through Sleep-amplified Memory Consolidation

Role: lead

NCT06247306Not ApplicableRecruiting

Using Neurofeedback to Understand the Relationship Between Stress and Alcohol Consumption

Role: lead

NCT04670081Phase 2Completed

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression

Role: lead